Safety of Glucagon Rescue Formulations: Risks Associated With Device Handling and Incomplete Dose Delivery

Author Name : Hidoc internal team

Diabetology

Page Navigation

Abstract

Glucagon rescue therapy is an essential intervention for severe hypoglycemia, particularly in people with insulin-treated diabetes who are unable to consume oral carbohydrates safely. Although modern formulations have simplified emergency treatment, clinically important hazards remain associated with device preparation, administration technique, inadequate dose delivery, delayed recognition of treatment failure, and inappropriate post-treatment monitoring. Traditional emergency kits require reconstitution and syringe-based injection, creating opportunities for incorrect assembly, leakage, needle-related injury, and failure to deliver the intended dose. Ready-to-use autoinjectors, prefilled syringes, and intranasal formulations reduce several procedural barriers but introduce formulation-specific risks, including activation errors, incomplete administration, incorrect positioning, nasal obstruction, and uncertainty regarding absorption. This review examines the epidemiology, mechanisms, risk factors, clinical manifestations, diagnosis, management, emerging therapies, and guideline-based recommendations relevant to glucagon rescue safety. Effective care requires product-specific education, repeated skills training, verification of administration, prompt escalation when consciousness does not improve, and continued glucose and clinical monitoring after rescue therapy.

Introduction

Severe hypoglycemia is a medical emergency characterized by cognitive impairment, seizure, loss of consciousness, or inability to self-treat. It most commonly affects individuals receiving insulin or insulin secretagogues, although it may also occur in patients with endocrine disorders, critical illness, malnutrition, renal or hepatic dysfunction, or medication-related glucose disturbances. Glucagon is used when oral glucose cannot be administered safely or when a person with diabetes is unresponsive. Its value is substantial because it can be administered by family members, caregivers, school personnel, coworkers, and emergency responders before professional medical support arrives.

The clinical effectiveness of glucagon depends not only on pharmacology but also on successful delivery of the full intended dose. In real-world emergencies, users may be distressed, unfamiliar with the device, or unable to distinguish between preparation and administration steps. A technically available rescue product can therefore fail if it is expired, stored incorrectly, assembled improperly, sprayed into an obstructed nostril, injected incompletely, or administered without subsequent assessment. Safety evaluation must consequently include human factors, usability, caregiver preparedness, and the clinical context in which rescue treatment is delivered.

Epidemiology / Disease Burden

Severe hypoglycemia remains a major burden in diabetes care. Risk is increased in people with recurrent hypoglycemia, impaired awareness, intensive insulin regimens, variable meal intake, strenuous exercise, alcohol use, cognitive impairment, and limited access to glucose monitoring. Children and adolescents may rely entirely on caregivers for recognition and treatment, while older adults may have atypical symptoms, polypharmacy, renal impairment, or difficulties with manual dexterity and vision. In these populations, the usability and reliability of glucagon delivery devices are especially important.

Studies of emergency glucagon use have consistently demonstrated that administration errors are common with reconstituted products. Reported problems include failure to mix the powder and diluent, withdrawal of an incorrect volume, injection into an unsuitable site, spillage, delayed administration, and abandonment of the procedure because the user cannot complete the steps. Ready-to-use products improve convenience and reduce preparation time, but they do not eliminate errors. Device unfamiliarity, incorrect activation, incomplete nasal delivery, and failure to maintain the required contact or position can still compromise treatment. These findings support prescribing glucagon together with structured education rather than treating the prescription alone as adequate protection.

Pathophysiology

Glucagon raises plasma glucose primarily by binding to hepatic glucagon receptors and activating adenylate cyclase, cyclic adenosine monophosphate, and protein kinase signaling. This promotes glycogenolysis and gluconeogenesis, increasing circulating glucose when hepatic glycogen stores and metabolic capacity are sufficient. The response may be attenuated in prolonged fasting, severe malnutrition, advanced liver disease, adrenal insufficiency, or after repeated hypoglycemic episodes that substantially deplete hepatic glycogen.

Incomplete dose delivery can produce a pharmacodynamic failure even when the product appears to have been used. A partially delivered dose may not achieve adequate receptor stimulation, while delayed administration allows progressive neuroglycopenia and may increase the risk of seizure, aspiration, trauma, or cardiac complications. Glucagon does not directly correct the underlying excess of exogenous insulin or an insulin secretagogue. Rebound hypoglycemia can therefore occur after an initial response, particularly with long-acting insulin, sulfonylureas, impaired renal clearance, or limited food intake. Nausea and vomiting, recognized effects of glucagon, may further complicate recovery and create aspiration risk in patients with reduced consciousness.

Risk Factors

Device-related risk is influenced by product design, storage, caregiver training, patient characteristics, and the emergency environment. Reconstituted kits require multiple sequential actions and are vulnerable to confusion between the diluent syringe and other household syringes. Users may inject too early, fail to transfer the powder completely, or draw up an incomplete volume. Poor lighting, panic, tremor, visual impairment, low health literacy, and lack of prior practice increase the likelihood of error.

Autoinjectors reduce preparation demands but may be mishandled if the user does not remove the safety mechanism, presses against an inappropriate location, lifts the device too soon, or does not recognize the completion signal. Prefilled syringes eliminate reconstitution but still require correct needle placement and full depression of the plunger. Intranasal formulations avoid needles and reconstitution, yet administration can be compromised by incorrect orientation, failure to insert the tip adequately, premature removal, nasal bleeding, severe congestion, or misunderstanding that the device must not be primed or tested before use. Children, individuals with nasal disease, and those receiving care in schools or community settings may require specific contingency planning.

Clinical Features

Successful rescue is generally followed by improvement in consciousness and behavior as glucose availability increases, although recovery may be delayed in prolonged hypoglycemia. Early adverse effects include nausea, vomiting, headache, dizziness, transient hypertension, and injection-site discomfort. More serious concerns include aspiration after vomiting, persistent neuroglycopenia, recurrent hypoglycemia, arrhythmia in vulnerable patients, and traumatic injury caused by seizure or collapse.

Failure to improve should not be attributed automatically to delayed glucagon action. It may indicate incorrect administration, an empty or damaged device, an inadequate dose, severe depletion of hepatic glycogen, alcohol-associated hypoglycemia, adrenal insufficiency, poisoning, stroke, seizure-related unconsciousness, or another cause of altered mental status. Clinicians and caregivers should treat the absence of response as a signal to activate emergency services and reassess the diagnosis and delivery process.

Diagnosis

Diagnosis requires immediate assessment of responsiveness, airway, breathing, circulation, and capillary or point-of-care glucose when available. A glucose measurement should not delay rescue treatment in a person with a known history of severe hypoglycemia and compatible features. After administration, glucose should be rechecked when feasible, and the patient should be observed for clinical recovery and recurrent hypoglycemia. A detailed history should document the suspected precipitant, insulin or secretagogue exposure, food intake, renal and hepatic function, alcohol use, timing of glucagon, product type, storage conditions, and whether the full dose was delivered.

When treatment appears ineffective, examination of the device may reveal an unactivated autoinjector, residual solution in a reconstituted vial, an unused nasal device, or evidence of leakage. These observations can distinguish pharmacologic nonresponse from delivery failure. Persistent coma, seizures, respiratory compromise, or uncertain diagnosis requires emergency evaluation, intravenous dextrose when appropriate, airway protection, and investigation for alternative or concurrent causes.

Treatment & Management

The immediate priority is protection from injury and aspiration, activation of emergency medical services, and administration of the prescribed glucagon product according to its instructions. Nothing should be placed in the mouth of an unconscious or convulsing person. Once the patient is awake, able to swallow safely, and clinically improving, rapidly absorbable carbohydrate should be followed by a longer-acting carbohydrate source or meal, unless a treating professional provides a different plan. The person should remain under observation because glucagon does not reliably prevent recurrence.

Healthcare professionals should inspect the delivered dose, obtain serial glucose measurements, and identify the precipitating cause. Sulfonylurea-associated hypoglycemia may be prolonged and can require hospital observation and specific therapy. Severe or recurrent episodes may warrant intravenous dextrose, endocrinology consultation, medication adjustment, renal or hepatic assessment, and review of nutrition and alcohol exposure. After recovery, a structured debrief should address what happened, whether the device functioned, which steps were difficult, and whether a replacement prescription is needed.

Prevention is a core component of management. Every person at significant risk should have an unexpired rescue product that is readily accessible, and close contacts should receive hands-on training using a trainer device when available. Education should cover recognition of severe hypoglycemia, calling for help, positioning the patient laterally when appropriate, product-specific administration, confirmation that the complete dose was delivered, and post-treatment monitoring. Training should be repeated after prescription changes, device changes, major cognitive or visual decline, or a rescue event.

Recent Advances / Emerging Therapies

Recent glucagon products have focused on eliminating reconstitution and reducing the number of steps required during an emergency. Stable liquid formulations, autoinjectors, prefilled syringes, and intranasal delivery systems can improve portability and caregiver acceptability. Human-factors research suggests that fewer preparation steps and clearer feedback may improve the probability of successful administration, although real-world performance remains dependent on familiarity and practice.

Future development is likely to emphasize connected diabetes technologies, automated alerts, caregiver notification, and integration with continuous glucose monitoring. These systems may shorten the time between detection and treatment but should not be considered substitutes for a physical rescue product or emergency assessment. Research is also needed to clarify performance in children, older adults, people with nasal pathology, individuals with very low glycogen reserves, and settings where the device is exposed to temperature extremes. Comparative studies should measure not only pharmacokinetics but also full-dose delivery, error rates, time to administration, and outcomes outside controlled clinical trials.

Guideline Recommendations

Major diabetes guidelines generally recommend prescribing glucagon for people at increased risk of clinically significant hypoglycemia and educating household members or caregivers in its use. Product selection should account for the user’s age, dexterity, vision, cognitive status, environment, nasal health, cost, availability, and caregiver preference. Instructions must be specific to the prescribed device because preparation and activation steps are not interchangeable across formulations.

Guideline-consistent practice includes maintaining an accessible, in-date supply; checking storage and packaging regularly; providing practical demonstrations; encouraging caregivers to call emergency services for severe hypoglycemia; and ensuring post-rescue carbohydrate intake and observation when safe. Clinicians should document education, assess confidence and competence, and review rescue performance after every event. Incomplete delivery, recurrent episodes, or delayed recovery should prompt reassessment of the treatment regimen, hypoglycemia awareness, monitoring technology, and social support.

Conclusion

Glucagon rescue therapy can be lifesaving, but its effectiveness depends on reliable delivery under stressful and time-critical conditions. Reconstitution errors, activation failures, incomplete injection, inadequate nasal administration, poor storage, and failure to monitor after treatment are clinically meaningful hazards. Newer ready-to-use formulations reduce procedural complexity and may improve caregiver performance, yet they require product-specific instruction and repeated practice. Safe implementation combines appropriate prescribing, accessible storage, hands-on education, rapid emergency activation, confirmation of clinical response, and evaluation for recurrent or alternative causes of hypoglycemia. A human-factors approach that treats device handling as part of clinical care is essential to maximizing the benefits and minimizing the risks of glucagon rescue.

Featured News
Featured Articles
Featured Events
Featured KOL Videos

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot